Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PreveCeutical Medical ( (TSE:PREV) ) has shared an update.
PreveCeutical Medical Inc. has announced a non-brokered private placement of up to 10 million units at $0.03 per unit, aiming to raise gross proceeds of up to $300,000. The proceeds will be used for paying outstanding payables, operating expenses, and general working capital. This strategic financial maneuver could potentially strengthen the company’s operational capabilities and enhance its market positioning in the health sciences industry, subject to certain conditions including CSE approval.
More about PreveCeutical Medical
PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products. It aspires to lead in preventive health sciences with five research and development programs, including dual gene therapy for diabetes and obesity, Sol-gel technology, Nature Identical™ peptides, nonaddictive analgesic peptides, and therapeutic products for athletes with concussions.
YTD Price Performance: 0.0%
Average Trading Volume: 109,653
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.42M
Find detailed analytics on PREV stock on TipRanks’ Stock Analysis page.
